<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04183660</url>
  </required_header>
  <id_info>
    <org_study_id>HVT-MB1</org_study_id>
    <nct_id>NCT04183660</nct_id>
  </id_info>
  <brief_title>A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System of Cardiac and Respiratory Support: The MOBYBOX Trial</brief_title>
  <official_title>A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System for Cardiac and Respiratory Support: The MOBYBOX Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemovent GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAXIS Medical, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hemovent GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate prospectively the safety and performance of the&#xD;
      MOBYBOX System in the veno-arterial configuration in patients with cardiorespiratory failure&#xD;
      or in the veno-venous configuration in patients with severe respiratory failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 22, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Rates of device and procedure related serious adverse events</measure>
    <time_frame>24 hours</time_frame>
    <description>Acute safety defined as rates of device and procedure related serious adverse events up to 24 hours post-intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device performance success</measure>
    <time_frame>every 4 hours while the patient receives ECMO using the MOBYBOX device</time_frame>
    <description>Device performance success (defined as the ability to establish either veno-arterial ECMO to support cardiorespiratory function and tissue oxygenation or veno-venous ECMO to support respiratory function and tissue oxygenation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event rate</measure>
    <time_frame>24 hours</time_frame>
    <description>Acute safety defined as rates adverse events up to 24 hours post-intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality up to 30 days post-intervention</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiac Failure</condition>
  <condition>Respiratory Failure</condition>
  <condition>Cardio-Respiratory Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MOBYBOX System</intervention_name>
    <description>extracorporeal cardiopulmonary support</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consented patients with cardiorespiratory failure or ith severe respiratory failure who&#xD;
        meet all of the inclusion and none of the exclusion criteria and in whom the investigator&#xD;
        intends to treat the patient with cardiopulmonary support using the Hemovent MOBYBOX&#xD;
        System.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with cardiac, respiratory or cardiorespiratory failure and 1 of the 5&#xD;
             following sets of findings:&#xD;
&#xD;
               1. A Murray score ≥ 3.0 and/or severe hypoxemia with A PaO2/FIO2 &lt; 100 mm on &gt; 0.9&#xD;
                  FIO2;&#xD;
&#xD;
               2. Uncompensated hypercapnia with pH &lt;7.2 despite a Pplateau &gt; 30 cm H20;&#xD;
&#xD;
               3. Significant air leak/bronchopleural fistula;&#xD;
&#xD;
               4. Need for intubation in a patient on lung transplant list;&#xD;
&#xD;
               5. Immediate cardiac or respiratory collapse (pulmonary embolus, blocked airway,&#xD;
                  unresponsive to optimal care);&#xD;
&#xD;
          -  Written consent of the patient or the legal guardian or external consulting physician&#xD;
             as designated and approved by the Ethics Committee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High pressure ventilation (FIO2 &gt; 0.9 and Pplateau &gt; 30 cm H2O) or high FIO2&#xD;
             requirements for more than 7 days;&#xD;
&#xD;
          -  Severe intracranial bleeding, which precludes the use of anticoagulation therapy or&#xD;
             any other inability to be anticoagulated&#xD;
&#xD;
          -  Excessive weight (&gt; 180 Kg)&#xD;
&#xD;
          -  Severe irreversible brain injury (e.g., hypoxic brain injury)&#xD;
&#xD;
          -  Inability to accept blood products;&#xD;
&#xD;
          -  Any condition or organ dysfunction that would limit the likelihood of overall benefit&#xD;
             from ECMO, such as severe, irreversible brain injury, hepatic and/or renal failure, or&#xD;
             untreatable metastatic cancer;&#xD;
&#xD;
          -  Immunosuppression with an absolute neutrophil count &lt; 400/mm3;&#xD;
&#xD;
          -  Patient has been treated with ECMO ≤ 48 hours.&#xD;
&#xD;
          -  For veno-veno ECMO in the setting of respiratory failure the following exclusion&#xD;
             criteria apply:&#xD;
&#xD;
          -  Severe pulmonary hypertension (mPAP &gt; 50 mm Hg)&#xD;
&#xD;
          -  Severe right or left sided heart failure (EF &lt; 25%)&#xD;
&#xD;
          -  For veno-arterial ECMO in the setting of cardiac insufficiency:&#xD;
&#xD;
          -  Severe aortic regurgitation&#xD;
&#xD;
          -  Aortic dissection.&#xD;
&#xD;
          -  The patient is moribund, or the patient has severe or deteriorating damage in critical&#xD;
             body systems.&#xD;
&#xD;
          -  Patient is participating in an investigational drug or device study trial that has not&#xD;
             reached the primary endpoint or that interferes with the current study endpoints.&#xD;
&#xD;
          -  Any condition that in the judgment of the investigators would interfere with the&#xD;
             subject's ability to provide informed consent, comply with study instructions, place&#xD;
             the subject at increased risk, or which might confound interpretation of study&#xD;
             results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillipp Lepper, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniklinikum Saarland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg Saar</city>
        <state>Saarland</state>
        <zip>66484</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

